These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 39117290

  • 1. SLFN11 and ATR as targets for overcoming cisplatin resistance in ovarian cancer cells.
    König P, Eichhorn JM, Suparman E, Bückreiß N, Cinatl J, Michaelis M, Bendas G.
    Biochim Biophys Acta Mol Basis Dis; 2024 Dec; 1870(8):167448. PubMed ID: 39117290
    [Abstract] [Full Text] [Related]

  • 2. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
    Nogales V, Reinhold WC, Varma S, Martinez-Cardus A, Moutinho C, Moran S, Heyn H, Sebio A, Barnadas A, Pommier Y, Esteller M.
    Oncotarget; 2016 Jan 19; 7(3):3084-97. PubMed ID: 26625211
    [Abstract] [Full Text] [Related]

  • 3. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
    Jo U, Murai Y, Chakka S, Chen L, Cheng K, Murai J, Saha LK, Miller Jenkins LM, Pommier Y.
    Proc Natl Acad Sci U S A; 2021 Feb 09; 118(6):. PubMed ID: 33536335
    [Abstract] [Full Text] [Related]

  • 4. DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
    Meng Y, Chen CW, Yung MMH, Sun W, Sun J, Li Z, Li J, Li Z, Zhou W, Liu SS, Cheung ANY, Ngan HYS, Braisted JC, Kai Y, Peng W, Tzatsos A, Li Y, Dai Z, Zheng W, Chan DW, Zhu W.
    Cancer Lett; 2018 Aug 01; 428():104-116. PubMed ID: 29704517
    [Abstract] [Full Text] [Related]

  • 5. The Impact of Integrin-Mediated Matrix Adhesion on Cisplatin Resistance of W1 Ovarian Cancer Cells.
    Wantoch von Rekowski K, König P, Henze S, Schlesinger M, Zawierucha P, Januchowski R, Bendas G.
    Biomolecules; 2019 Nov 26; 9(12):. PubMed ID: 31779287
    [Abstract] [Full Text] [Related]

  • 6. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
    Huntoon CJ, Flatten KS, Wahner Hendrickson AE, Huehls AM, Sutor SL, Kaufmann SH, Karnitz LM.
    Cancer Res; 2013 Jun 15; 73(12):3683-91. PubMed ID: 23548269
    [Abstract] [Full Text] [Related]

  • 7. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA.
    Oncotarget; 2017 Apr 25; 8(17):28575-28587. PubMed ID: 28212573
    [Abstract] [Full Text] [Related]

  • 8. Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.
    Tang SW, Thomas A, Murai J, Trepel JB, Bates SE, Rajapakse VN, Pommier Y.
    Clin Cancer Res; 2018 Apr 15; 24(8):1944-1953. PubMed ID: 29391350
    [Abstract] [Full Text] [Related]

  • 9. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma.
    Shi Q, Shen LY, Dong B, Fu H, Kang XZ, Yang YB, Dai L, Yan WP, Xiong HC, Liang Z, Chen KN.
    Cancer Lett; 2018 Sep 28; 432():56-68. PubMed ID: 29890208
    [Abstract] [Full Text] [Related]

  • 10. Prognostic impact of Schlafen 11 in bladder cancer patients treated with platinum-based chemotherapy.
    Taniyama D, Sakamoto N, Takashima T, Takeda M, Pham QT, Ukai S, Maruyama R, Harada K, Babasaki T, Sekino Y, Hayashi T, Sentani K, Pommier Y, Murai J, Yasui W.
    Cancer Sci; 2022 Feb 28; 113(2):784-795. PubMed ID: 34808009
    [Abstract] [Full Text] [Related]

  • 11. Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR.
    Mao S, Chaerkady R, Yu W, D'Angelo G, Garcia A, Chen H, Barrett AM, Phipps S, Fleming R, Hess S, Koopmann JO, Dimasi N, Wilson S, Pugh K, Cook K, Masterson LA, Gao C, Wu H, Herbst R, Howard PW, Tice DA, Cobbold M, Harper J.
    Mol Cancer Ther; 2021 Mar 28; 20(3):541-552. PubMed ID: 33653945
    [Abstract] [Full Text] [Related]

  • 12. Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.
    Wang QE, Milum K, Han C, Huang YW, Wani G, Thomale J, Wani AA.
    Mol Cancer; 2011 Mar 08; 10():24. PubMed ID: 21385444
    [Abstract] [Full Text] [Related]

  • 13. Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition.
    Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y.
    Oncotarget; 2016 Nov 22; 7(47):76534-76550. PubMed ID: 27708213
    [Abstract] [Full Text] [Related]

  • 14. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
    Winkler C, King M, Berthe J, Ferraioli D, Garuti A, Grillo F, Rodriguez-Canales J, Ferrando L, Chopin N, Ray-Coquard I, Delpuech O, Rinchai D, Bedognetti D, Ballestrero A, Leo E, Zoppoli G.
    JCI Insight; 2021 Sep 22; 6(18):. PubMed ID: 34549724
    [Abstract] [Full Text] [Related]

  • 15. SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer.
    Kundu K, Cardnell RJ, Zhang B, Shen L, Stewart CA, Ramkumar K, Cargill KR, Wang J, Gay CM, Byers LA.
    Transl Lung Cancer Res; 2021 Nov 22; 10(11):4095-4105. PubMed ID: 35004241
    [Abstract] [Full Text] [Related]

  • 16. Methylation of SLFN11 is a marker of poor prognosis and cisplatin resistance in colorectal cancer.
    He T, Zhang M, Zheng R, Zheng S, Linghu E, Herman JG, Guo M.
    Epigenomics; 2017 Jun 22; 9(6):849-862. PubMed ID: 28403629
    [Abstract] [Full Text] [Related]

  • 17. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    Gralewska P, Gajek A, Marczak A, Rogalska A.
    J Hematol Oncol; 2020 Apr 21; 13(1):39. PubMed ID: 32316968
    [Abstract] [Full Text] [Related]

  • 18. Uncovering miRNA-mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors.
    Biegała Ł, Kołat D, Gajek A, Płuciennik E, Marczak A, Śliwińska A, Mikula M, Rogalska A.
    Cells; 2024 May 17; 13(10):. PubMed ID: 38786089
    [Abstract] [Full Text] [Related]

  • 19. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
    Peasland A, Wang LZ, Rowling E, Kyle S, Chen T, Hopkins A, Cliby WA, Sarkaria J, Beale G, Edmondson RJ, Curtin NJ.
    Br J Cancer; 2011 Jul 26; 105(3):372-81. PubMed ID: 21730979
    [Abstract] [Full Text] [Related]

  • 20. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.
    Teng PN, Bateman NW, Darcy KM, Hamilton CA, Maxwell GL, Bakkenist CJ, Conrads TP.
    Gynecol Oncol; 2015 Mar 26; 136(3):554-61. PubMed ID: 25560806
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.